Impact of Site Size on Data Quality in Early Alzheimer’s Disease Clinical Trials
Alan Kott, Xingmei Wang, Petra Reksoprodjo, Andrei Iacob, David S. Miller · 2025
Read Impact of Site Size on Data Quality in Early Alzheimer’s Disease Clinical Trials by Alan Kott, Xingmei Wang, Petra Reksoprodjo, Andrei Iacob, David S. Miller (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11712610.txt.
Description
Alan Kott and co-authors, in a 2025 paper, ask whether small trial sites hurt data quality in early Alzheimer's disease trials. Sponsors depend on sites to pick the right patients and to rate symptoms in a sound, steady way. Sites that enroll few people cost much money and effort, and may add errors.
The team drew data from three large early dementia trials with 834 sites in all. They split sites into those with more than five patients and those with five or fewer. Data quality meant errors in giving and scoring the tests used in the trials. Those error counts were summed per site and compared between the two groups, with trial and size taken into account. Past work in a related field found most sites enrolled very few patients.
Catalog record
| CREATOR | Alan Kott, Xingmei Wang, Petra Reksoprodjo, Andrei Iacob, David S. Miller |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |